- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
NICE Rejects Provenge, Says Treatment is Not Cost-Effective
The governing body for public health in the UK, National Institute for Health and Care Excellence, has refused to fund Provenge citing a high-price for the benefit the tretament provides. This may not be the best news for Valeant Pharmaceuticals which recently bought the regimen from the bankrupt Dendreon Corp.
The National Institute for Health and Care Excellence has published 2 sets of final guidelines for the National Health Service(NHS), endorsing the use of Pfizer’s Inlyta (axitinib) in kidney cancer but rejecting Dendreon’s Provenge (sipuleucel-T) in prostate cancer.
Inlyta is being recommended as a second-line option for treating adults with advanced renal cell carcinoma after treatment with a first-line tyrosine kinase inhibitor or a cytokine has failed.
The Institute previously concluded that the most plausible cost per QALY (quality-adjusted life year) for the drug after first-line treatment with Pfizer’s tyrosine kinase inhibitor Sutent (sunitinib) would be around halfway between £33,500 and £52,900, and after a cytokine £33,000.
On the downside, Provenge will not be funded on the NHS because the cost regulator has concluded that available evidence shows the price for the drug “is too high for the benefit it may provide”.
Read more at PharmaTimes: http://bit.ly/1EQ9mRV
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Bridging Cancer Care Gaps and Overcoming Medical Mistrust
November 13th 2024In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.
Read More
How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care
November 13th 2024Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.
Read More
